- Key Facts and First-Day Trends
- Post-IPO Valuation Check
- Should You Hold or Sell Now?
- What Investors Should Track Now
- Final Take
Corona Remedies’ ₹655.37 crore IPO (Dec 8-10, 2025) ended with a solid debut, as the stock opened meaningfully above its ₹1,062 issue price and even hit ₹1,497.8 intraday. Now, after the strong listing, the discussion has shifted from “will it list well” to “can earnings justify the new price”. This blog breaks down the key listing-day numbers, what changed (and what did not), and what to track next.
Key Facts and First-Day Trends
- IPO Price: ₹1,062 per share
- Listing Price: ₹1,470 per share (38.4% above issue price on NSE)
- Market Capitalization (at listing): ~₹9,000 crore
- Track the live share price of Corona Remedies here.
Post-IPO Valuation Check
- Updated P/E (price-to-earnings): about 60.2x at ₹1,470 using FY25 profit of ₹149 crore and listed market cap ~₹9,000 crore. IPO P/E was about 43.47x at ₹1,062 (as per FY25 numbers shared in the RHP).
- What changed: The stock rerated from ~43.5x to ~60x on Day 1, so the market is now pricing in faster growth and or better margins ahead.
- Updated P/S (price-to-sales): about 7.5x at ₹9,000 crore market cap and FY25 revenue of ₹1,196 crore.
- Peer line: At IPO, valuation was near the peer average P/E (~43.74x), but post-listing, it is well above that average.
Also Read: CORONA Remedies IPO Explained
Should You Hold or Sell Now?
- Short-term trader: A strong listing often brings volatility; consider using a strict stop-loss mindset because post-pop pullbacks are common when early gains get booked.
- Medium-term investor: The stock now trades at a higher earnings multiple than at IPO, so it may need clean quarterly execution to support the new price.
- Long-term investor: If the business keeps scaling its India-focused branded portfolio, long-term holders usually care more about revenue growth, margins, and cash conversion than Day-1 price.
- Balanced action: Some investors consider partial profit-booking after a big listing jump, while keeping exposure for a longer runway, especially ahead of lock-in dates.
What Investors Should Track Now
- Quarterly results: Watch whether revenue stays strong and whether PAT and EBITDA margins hold up from FY25 levels.
- Anchor lock-in dates: Jan 9, 2026 (50% shares) and Mar 10, 2026 (remaining); these windows can bring 5-15% short-term selling pressure in many IPOs.
- Cash flow and receivables: Any rise in working capital can reduce cash available for growth, especially since the IPO was fully OFS and does not add fresh cash to the company.
- Margin trend: EBITDA margin was 20.55% in FY25; if input costs rise or pricing weakens, the market may rethink the higher post-listing valuation.
- Growth funding: With no IPO proceeds coming into the business (OFS), track how expansion is funded via internal accruals or borrowing.
- Management updates: Any commentary on capacity additions, product pipeline, or specialist-led growth will matter more now because the stock is priced for delivery.
For complete information, visit Corona Remedies’ official IPO page here.
Final Take
Corona Remedies delivered a strong listing at ₹1,470, but the post-listing valuation is now much richer than the IPO’s already full pricing, so future returns may depend more on execution than sentiment.
A practical next step is to mark the two anchor lock-in dates and the next two quarterly results on your calendar, then judge whether growth and margins are tracking well enough for the higher multiple.
For more IPOs, check INDmoney’s IPO tracker here.
Disclaimer
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. The securities are quoted as an example and not as a recommendation. This is nowhere to be considered as advice, recommendation, or solicitation of an offer to buy or sell or subscribe for securities. INDStocks SIP / Mini Save is a SIP feature that enables Customer(s) to save a fixed amount on a daily basis to invest in Indian stocks. INDstocks Private Limited (formerly known as INDmoney Private Limited) 616, Level 6, Suncity Success Tower, Sector 65, Gurugram, 122005, SEBI Stock Broking Registration No: INZ000305337, Trading and Clearing Member of NSE (90267, M70042) and BSE, BSE StarMF (6779), SEBI Depository Participant Reg. No. IN-DP-690-2022, Depository Participant ID: CDSL 12095500, Research Analyst Registration No. INH000018948 BSE RA Enlistment No. 6428. Refer to https://indstocks.com/pricing?type=indian-stocks; https://www.indstocks.com/page/indian-stocks-sip-terms-and-condition for further details.